Recent Advances in Asthma Management

Support: No funding was received in the publication of this article. The treatment of asthma has improved greatly during the last two decades, and deaths from the disease have decreased. Despite these advances, many asthma patients fail to achieve optimal asthma control as defined by international guidelines. Severe asthma is associated with high risk of exacerbations and death. Definitions of severe asthma vary but, according to European Respiratory Society (ERS)/American Thoracic Society (ATS) and Global Initiative for Asthma (GINA) guidelines, severe asthma is asthma that requires treatment with high doses of inhaled corticosteroids plus a second controller, and/or systemic corticosteroids, to prevent it from becoming uncontrolled, or remains uncontrolled despite this therapy. In an expert interview, Professor Barnes discusses the latest advances in the management of both mild and severe asthma.

[1]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[2]  E. Bateman,et al.  As‐Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma , 2018, The New England journal of medicine.

[3]  E. Bateman,et al.  Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma , 2018, The New England journal of medicine.

[4]  J. Corren,et al.  Tezepelumab in Adults with Uncontrolled Asthma , 2017, The New England journal of medicine.

[5]  C. Jenkins,et al.  The paradoxes of asthma management: time for a new approach? , 2017, European Respiratory Journal.

[6]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[7]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[8]  T. To,et al.  Asthma deaths in a large provincial health system. A 10-year population-based study. , 2014, Annals of the American Thoracic Society.

[9]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[10]  E. Kerwin,et al.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. , 2013, American journal of respiratory and critical care medicine.

[11]  I. Pavord,et al.  EAACI position statement on asthma exacerbations and severe asthma , 2013, Allergy.

[12]  J. Bird,et al.  Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial , 2013, Pediatrics.

[13]  S. Willsie.  Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia , 2010 .

[14]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[15]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[16]  W. Busse,et al.  Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study , 2006, BMC pulmonary medicine.